Dr. Knox is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Dept Radiation Oncology Cancer Center
Palo Alto, CA 94304Phone+1 650-723-6171Fax+1 650-725-8231
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 1986 - 1990
University of California Davis HealthInternship, Internal Medicine, 1985 - 1986
Stanford University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1986 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCL Start of enrollment: 2004 Sep 01
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy Start of enrollment: 2007 Jan 01
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Start of enrollment: 2011 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees.Ana P Kiess, Robert F Hobbs, Bryan Bednarz, Susan J Knox, Ruby Meredith
International Journal of Radiation Oncology, Biology, Physics. 2022-07-15 - 4 citationsBasics of Physics and Radiobiology for Radiopharmaceutical Therapies.Keara K English, Susan Knox, Stephen A Graves, Ana P Kiess
Practical Radiation Oncology. 2022-06-18 - 71 citationsGenomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou
Cancer Discovery. 2021-06-28
Press Mentions
Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2February 22nd, 2023
Stanford Medical Students Celebrate Match Day VirtuallyMarch 22nd, 2021
Eighty-Five Medical Students Meet Their MatchesMarch 15th, 2019
Grant Support
- Protocol Review And Monitoring System (PRMS)National Cancer Institute2007–2009
- Clinical Trial: Phase II Study Of Bexxar In Relapsed/Refractory DlclNational Center For Research Resources2008
- Clinical Trial: Bexxar Combined With External Beam Radiation Therapy For PatientNational Center For Research Resources2008
- Phase II Study Of Bexxar In Relapsed/Refractory DlclNational Center For Research Resources2006–2007
- Anti B1 Antibody For Nonhodgkins LymphomaNational Center For Research Resources2000–2001
- Phase II Multicenter Trial Of 90 Yttrium DOTA Biotin In Subjects W/ CancerNational Center For Research Resources1999–2000
- Iodine Anti B1 Murine Radioimmunotherapy For Chemotherapy LymphomaNational Center For Research Resources1999–2000
- Anti-B1 (MURINE) In Chemotherapy-Refractory Low Grade Nonhodgkin'S LymphomaNational Center For Research Resources1997–2000
- Study Of 90 Yttrium/Dota/Biotin Localization In Advanced CancerNational Center For Research Resources1996–2000
- Pivotal Phase II/III Of Murine Radioimmunotherapy For LymphomasNational Center For Research Resources1998–1999
- BCL-2, Na+/K+ Atpase And Radiation Induced ApoptosisNational Cancer Institute1996–1998
- Radiobiology Of Low Dose Rate RadioimmunotherapyNational Cancer Institute1994–1997
- Intravenously Administered 90y-Cyi-356 In Metastatic Prostate CancerNational Center For Research Resources1996
- B Cell Lymphoma With 90y-Labeled B1 (Anti-Cd20) Monoclonal AntibodyNational Center For Research Resources1996
- Radiobiology Of Low-Dose Rate RadioimmunotherapyNational Cancer Institute1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
